

		Complete if Known Application Number 10/526,120 Filing Date July 14, 2005 First Named Inventor Chua et al. Group Art Unit 1644 Examiner Name Nora Maureen Rooney Attorney Docket Number 11747.105002 NUS002	
Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			
Sheet	1	of	4

4297845 1.DOC

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	U.S. Patent Document Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	4,722,848	A	Paoletti et al.	02-02-1988	
	AB	4,882,278	A	Mekalanos	11-21-1989	
	AC	4,920,209	A	Davis et al.	04-24-1990	
	AD	5,015,580	A	Christou et al.	05-14-1991	
	AE	5,168,062	A	Stinski	12-01-1992	
	AF	5,283,185	A	Epand et al.	02-01-1994	
	AG	5,364,773	A	Paoletti et al.	11-15-1994	
	AH	5,405,758	A	Oka et al.	04-11-1995	
	AI	5,433,948	A	Thomas et al.	07-18-1995	
	AJ	5,527,928	A	Nantz et al.	06-18-1996	
	AK	5,552,142	A	Thomas et al.	09-03-1996	
	AL	5,556,953	A	Zhang et al.	09-17-1996	
	AM	5,710,126	A	Griffith et al.	01-20-1998	
	AN	5,770,202	A	Thomas et al.	06-23-1998	
	AO	5,773,002	A	Thomas et al.	06-30-1998	
	AP	5,798,099	A	Yuuki et al.	08-25-1998	
	AQ	5,849,522	A	Fleckenstein et al.	12-15-1998	
	AR	5,869,288	A	Chapman et al.	02-09-1999	
	AS	5,876,722	A	Yuuki et al.	03-02-1999	
	AT	5,948,891	A	Staunton et al.	09-07-1999	
	AU	5,958,891	A	Hsu et al.	09-28-1999	
	AV	5,973,132	A	Thomas et al.	10-26-1999	
	AW	6,060,057	A	Thomas et al.	05-09-2000	
	AX	6,077,517	A	Thomas et al.	06-20-2000	
	AY	6,086,897	A	Thomas et al.	07-11-2000	
	AZ	6,147,201	A	Thomas et al.	11-14-2000	
	AAA	6,214,358	B1	Singh et al.	04-10-2001	
	AAB	6,268,491	B1	Garman et al.	07-31-2001	
	AAC	6,441,157	B1	Singh et al.	08-27-2002	

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document Office	Number	Kind (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	AAD	WO	88/06626	A1	Whitehead Inst. Biomed. Res.	09-07-1988

Examiner Signature	/Nora Rooney/	Date Considered	11/24/2008
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

4

Application Number

Complete if Known

10/526,120

Filing Date

July 14, 2005

First Named Inventor

Chua et al.

Group Art Unit

1644

Examiner Name

Nora Maureen Rooney

Attorney Docket Number

11747.105002 NUS002

4297845, L.DOC

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document Office ²	Number	Kind (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6
	BA	WO	90/00594	A2	Whitehead Inst., et al.	01-25-1990		
	BB	WO	90/11092	A1	Vical, Inc.; Wisc. Alum. R.F..	10-04-1990		
	BC	WO	91/00359	A1	Agracetus, Inc.	01-10-1991		
	BD	WO	91/13157	A1	Commonwealth Sci. Ind. Res.	09-05-1991		
	BE	WO	91/15501	A1	Yale Univ.	10-17-1991		
	BF	WO	92/01796	A1	SmithKlineBeecham Biol.	02-06-1992		
	BG	WO	92/11354	A1	Gen. Hosp. Corp.; Harvard	07-09-1992		
	BH	WO	92/11361	A1	Gen. Hosp. Corp.; Harvard	07-09-1992		
	BI	WO	92/21376	A1	Med Immune Inc.	12-10-1992		
	BJ	WO	93/17706	A1	Agracetus, Inc.	09-16-1993		
	BK	WO	93/18759	A1	Baylor Coll. Med.	09-30-1993		
	BL	WO	93/19768	A1	Univ. California	10-14-1993		
	BM	WO	94/01533	A1	Harvard Coll.; Virus Res. Inst.	01-20-1994		
	BN	WO	94/19482	A1	Gen. Hosp. Corp; Harvard	09-01-1994		
	BO	WO	94/25608	A1	Baylor Coll. Med.	11-10-1994		
	BP	WO	95/02397	A1	Univ. California	01-26-1995		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	BQ	ARRUDA, L.K., "Sensitization to Blomia tropicalis in patients with asthma and identification of allergen Blo t 5," <i>Am. J. Respir. Crit. Care Med.</i> , 155(1):343-350 (January 1997).
	BR	BLAGOVESHCHENSKAYA, A.D., et al., "A balance of opposing signals within the cytoplasmic tail controls the lysosomal targeting of P-selectin," <i>J. Biol. Chem.</i> , 273(43):27896-27903 (October 23, 1998).
	BS	BLAGOVESHCHENSKAYA, A.D., et al., "Lysosomal targeting of P-selectin is mediated by a novel sequence within its cytoplasmic tail," <i>J. Biol. Chem.</i> , 273(5):2729-2737 (January 30, 1998).
	BT	BONIFAZ, L., et al., "Efficient targeting of protein antigen to the dendritic cell receptor DEC- 205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance," <i>J. Exp. Med.</i> , 196(12):1627-1638 (December 16, 2002).
	BU	BOSHART, M., et al., "A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus," <i>Cell</i> , 41(2):521-530 (June 1985).
	BV	CALVO, P.A., et al., "a cytoplasmic sequence in human tyrosinase defines a second class of di-leucine based sorting signals for late endosomal and lysosomal delivery," <i>J. Biol. Chem.</i> , 274(18):12780-12789 (April 30, 1999).

Examiner
Signature

/Nora Rooney/

Date Con-
sidered

11/24/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known Application Number 10/526,120 Filing Date July 14, 2005 First Named Inventor Chua et al. Group Art Unit 1644 Examiner Name Nora Maureen Rooney Attorney Docket Number 11747.105002 NUS002	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			
Sheet	3	of	4

4297845 1.DOC

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	CA	CHEW, J.L., et al., "Chitosan nanoparticles containing plasmid DNA encoding house dust mite allergen, Der p 1 for oral vaccination in mice," <i>Vaccine</i> , 21(21-22):2720-2729 (June 20, 2003).	
	CB	CHUA, K.Y., et al., "Sequence analysis of cDNA coding for a major house dust mite allergen, Der p 1. Homology with cysteine proteases," <i>J. Exp. Med.</i> , 167(1):175-182 (January 1, 1988).	
	CC	FLYNN, J.L., "Recombinant BCG as an antigen delivery system," <i>Cell. Mol. Biol. (Noisy-le-grand)</i> , 40 (Suppl. 1):31-36 (1994).	
	CD	FUKUMOTO, H., et al., "Cloning and characterization of the major insulin-responsive glucose transporter expressed in human skeletal muscle and other insulin responsive tissues," <i>J. Biol. Chem.</i> , 264(14):7776-7779 (May 15, 1989).	
	CE	GHOSH, P.K., et al., "Identification of a promoter component involved in positioning the 5' termini of simian virus 40 early mRNAs," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 78(1):100-104 (January 1981).	
	CF	GOKAY, K.E., "Cytoplasmic signals mediate apical early endosomal targeting of endotubulin in MDCK Cells," <i>Traffic</i> , 2(7):487-500 (July 2, 2001).	
	CG	GOKAY, K.E., "Targeting of an apical endosomal protein to endosomes in Madin-Darby canine kidney cells requires two sorting motifs," <i>Traffic</i> , 1(4):354-365 (April 2000).	
	CH	GORMAN, C.M., et al., "The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 79(22):6777-6781 (November 1982).	
	CI	HIGH, N., et al., "IpaB of Shigella flexneri causes entry into epithelial cells and escape from the phagocytic vacuole," <i>EMBO J.</i> , 11(5):1991-1999 (May 1992).	
	CJ	JOHNSTON, G.I., et al., "Structure of the human gene encoding granule membrane protein-140, a member of the selectin family of adhesion receptors for leukocytes," <i>J. Biol. Chem.</i> , 265(34):21381-21385 (December 5, 1990).	
	CK	KATO, M., et al., "cDNA cloning of human DEC-205, a putative antigen-uptake receptor on dendritic cells," <i>Immunogenetics</i> , 47(6):442-450 (May 1998).	
	CL	KIENY, M.P., et al., "Expression of rabies virus glycoprotein from a recombinant vaccinia virus," <i>Nature</i> , 312(5990):163-166 (November 8-14, 1984).	
	CM	KWON, S.S., et al., "The effect of vaccination with DNA encoding murine T-cell epitopes on the Der p 1 and 2 induced immunoglobulin E synthesis," <i>Allergy</i> , 56(8):741-748 (August 2001).	
	CN	McCUTCHAN, T.F., et al., "DNA sequences similar to those around the simian virus 40 origin of replication are present in the monkey genome," <i>Proc. Natl. Acad. Sci. USA</i> , 78(1):95-99 (January 1981).	
	CO	MEDAGLINI, D., et al., "Mucosal and systemic immune responses to a recombinant protein expressed on the surface of the oral commensal bacterium Streptococcus gordonii after oral colonization," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 92(15):6868-6872 (July 18, 1995).	
	CP	MEKALANOS, J.J., et al., "Cholera toxin genes: nucleotide sequence, deletion analysis and vaccine development," <i>Nature</i> , 306(5943):551-557 (December 8-14, 1983).	

Examiner Signature	/Nora Rooney/	Date Considered	11/24/2008
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known Application Number 10/526,120 Filing Date July 14, 2005 First Named Inventor Chua et al. Group Art Unit 1644 Examiner Name Nora Maureen Rooney Attorney Docket Number 11747.105002 NUS002	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			
Sheet	4	of	4

4297845 1.DOC

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	DA	NAKAYAMA, K., et al., "Construction of an ASD+ Expression-Cloning Vector: Stable Maintenance and High Level Expression of Cloned Genes in a <i>Salmonella</i> Vaccine Strain," <i>Nature Biotechnology</i> (<i>BioTechnology</i>), 6:693-697 (1988).
	DB	NIWA, H., et al., "Efficient selection for high-expression transfectants with a novel eukaryotic vector," <i>Gene</i> , 108(2):193-199 (December 15, 1991).
	DC	NORCOTT, J.P., et al., "Targeting of P-selectin to two regulated secretory organelles in PC12 cells," <i>J. Cell Biol.</i> , 134(5):1229-1240 (September 1996).
	DD	RODRIGUEZ, F., et al., "CD4+ T cells induced by a DNA vaccine: immunological consequences of epitope-specific lysosomal targeting," <i>J. Virology</i> , 75(21):10421-10430 (November 2001).
	DE	SANDOVAL, I.V., et al., "The residues Leu(Ile)475-Ile(Leu, Val, Ala)476, contained in the extended carboxyl cytoplasmic tail, are critical for targeting of the resident lysosomal membrane protein LIMP II to lysosomes," <i>J. Biochemistry</i> , 269(9): 6622-6631 (March 4, 1994).
	DF	SHEWAN, A.M., et al., "The cytosolic C terminus of the glucose transporter GLUT4 contains an acidic cluster endosomal targeting motif distal to the dileucine signal," <i>Biochem. J.</i> , 350 Pt 1:99-107 (August 15, 2000).
	DG	SIZEMORE, D.R., et al., "Attenuated <i>Shigella</i> as a DNA delivery vehicle for DNA-mediated immunization," <i>Science</i> , 270(5234):299-302 (October 13, 1995).
	DH	STRAUSBERG, R.L., et al., "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences," <i>Proc. Natl Acad. Sci. USA</i> , 99(26):16899-903 (December 24, 2002) (Epub December 11, 2002).
	DI	TANG, D.C., et al., "Genetic immunization is a simple method for eliciting an immune response," <i>Nature</i> 356(6365):152-154 (March 12, 1992).
	DJ	TARTAGLIA, J., et al., "NYVAC: a highly attenuated strain of vaccinia virus," <i>Virology</i> , 188(1):217-232 (May 1992).
	DK	TAYLOR, J., et al., "Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species," <i>Vaccine</i> , 13(6):539-549 (April 1995).
	DL	USHIYAMA, S., et al., "Structural and functional characterization of monomeric soluble P-selectin and comparison with membrane P-selectin," <i>J. Biol. Chem.</i> , 268(20):15229-15237 (July 15, 1993).
	DM	VEGA, M.A., et al., "Cloning, sequencing, and expression of a cDNA encoding rat LIMP 11, a novel 74-kDa lysosomal membrane protein related to the surface adhesion protein CD36," <i>J. Biol. Chem.</i> , 266(25):16818-16824 (September 5, 1991).
	DN	VEGA, M.A., et al., "Targeting of lysosomal integral membrane protein LIMP II. The tyrosine-lacking carboxyl cytoplasmic tail of LIMP II is sufficient for direct targeting to lysosomes," <i>J. Biol. Chem.</i> , 266(25):16269-16272 (September 5, 1991).

Examiner Signature	/Nora Rooney/	Date Considered	11/24/2008
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/